Here, by developing a significant series of ccRCC patient‐derived orthotopic PDOX mouse models, we sought to investigate the consequence of VEGF pathway inhibition on RCC invasiveness and metastatic potential and to identify new biomarkers to predict the aggressive capacity of tumors. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.